Food and healthcare company Orion Group has made a bold step to expand its biotech interests, buying around a quarter of LegoChem Biosciences (Kosdaq: 141080) for $420 million.
The move will make Orion the largest holder of shares in LegoChem, a Kosdaq-listed biotech headquartered in the central South Korean city of Daejeon.
Led by a Hong Kong-based subsidiary, Pan Orion, the move will make LegoChem an affiliate which retains its existing management and operational structure.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze